Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

[1]  P. Stephens,et al.  BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy , 2018, Pigment cell & melanoma research.

[2]  T. Venesio,et al.  BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report , 2017, Melanoma research.

[3]  Nancy R. Zhang,et al.  Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. , 2017, Cell reports.

[4]  Yiling Lu,et al.  A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. , 2017, Cell reports.

[5]  Q. Lan,et al.  CSIG-19. FHL2 INTERACTS WITH EGFRVIII TO PROMOTE GLIOBLASTOMA GROWTH , 2017 .

[6]  P. Siegel,et al.  Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer☆ , 2017, Pharmacology & therapeutics.

[7]  Yutaka Suzuki,et al.  Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study , 2017, British Journal of Cancer.

[8]  G. Stoffels,et al.  Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease , 2017, Oncology reports.

[9]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[10]  J. Desai,et al.  517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC) , 2017 .

[11]  M. Ychou,et al.  473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results , 2017 .

[12]  B. Taylor,et al.  Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS , 2017, Nature.

[13]  M. Barbacid,et al.  A Braf kinase-inactive mutant induces lung adenocarcinoma , 2017, Nature.

[14]  H. Kim,et al.  Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition , 2017, Oncogene.

[15]  W. Hahn,et al.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.

[16]  R. Sullivan,et al.  Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity. , 2017 .

[17]  K. Flaherty,et al.  Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. , 2017 .

[18]  E. White,et al.  BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma , 2017, Clinical Cancer Research.

[19]  Jesse S. Voss,et al.  Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. McQuade,et al.  Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon‐V600 mutations in cutaneous melanoma patients , 2017, Cancer.

[21]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[22]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[23]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[24]  G. Fontanini,et al.  Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months , 2017, Experimental Hematology & Oncology.

[25]  Kathleen R. Cho,et al.  BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis , 2017, eLife.

[26]  G. Bollag,et al.  Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer , 2016, Proceedings of the National Academy of Sciences.

[27]  M. Herlyn,et al.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. , 2016, Cancer cell.

[28]  M. Brose,et al.  Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[29]  E. Richtig,et al.  Usage and Distribution for Commercial Purposes Requires Written Permission. Two Case Reports of Rare Braf Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options , 2022 .

[30]  L. Decoster,et al.  Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib , 2016, Oncotarget.

[31]  D. Zillikens,et al.  [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations]. , 2016, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[32]  J. Grilley-Olson,et al.  A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.

[33]  Lynda Chin,et al.  MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB , 2016, Clinical Cancer Research.

[34]  A. Delmonte,et al.  Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report , 2016, BMC Cancer.

[35]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[36]  J. Wargo,et al.  Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy , 2016, Current Oncology Reports.

[37]  J. Desai,et al.  Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). , 2016 .

[38]  H. Groen,et al.  An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). , 2016 .

[39]  A. Neumann,et al.  Ansprechen eines BRAFL597Q-mutierten Melanoms auf Trametinib , 2016, Der Hautarzt.

[40]  Tae Min Kim,et al.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[41]  P. Stephens,et al.  Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. , 2016, Cancer cell.

[42]  C. Yeh,et al.  Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients , 2016, Oncotarget.

[43]  Shih-Hsun Chen,et al.  Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. , 2016, Cancer discovery.

[44]  D. Louis,et al.  Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. , 2016, Journal of the National Cancer Institute.

[45]  M. Preusser,et al.  BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors , 2016, Expert opinion on investigational drugs.

[46]  Lisa M Haley,et al.  Clinical detection and categorization of uncommon and concomitant mutations involving BRAF , 2015, BMC Cancer.

[47]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[48]  V. Moreno,et al.  A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation , 2015, Anti-cancer drugs.

[49]  Bastien Cabarrou,et al.  Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  P. Gibbs,et al.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  O. Abdel-Wahab,et al.  BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.

[53]  Kai Wang,et al.  The distribution of BRAF gene fusions in solid tumors and response to targeted therapy , 2015, International journal of cancer.

[54]  I. Yeh,et al.  Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion , 2015, Pigment cell & melanoma research.

[55]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[56]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[57]  J. Malvehy,et al.  Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma. , 2015, JAMA dermatology.

[58]  M. Therrien,et al.  Regulation of RAF protein kinases in ERK signalling , 2015, Nature Reviews Molecular Cell Biology.

[59]  Sabine Tejpar,et al.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  C. Belani,et al.  Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer , 2015, PloS one.

[61]  M. Berger,et al.  Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients , 2015, Clinical Cancer Research.

[62]  N. Carragher,et al.  Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma , 2015, Cancer cell.

[63]  Marc Therrien,et al.  Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation , 2014, Nature Structural &Molecular Biology.

[64]  M. Preusser,et al.  BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. , 2014, Current opinion in neurology.

[65]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[66]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[67]  M. Ladanyi,et al.  Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  M. Millward,et al.  Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma , 2014, Melanoma research.

[69]  Ariana Peck,et al.  Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. , 2014, Cancer cell.

[70]  Jared C Malke,et al.  Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma , 2014, The Journal of investigative dermatology.

[71]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[72]  John Y. K. Lee,et al.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas , 2014, Nature Genetics.

[73]  P. Stephens,et al.  BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition , 2013, Clinical Cancer Research.

[74]  N. Rosen,et al.  Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.

[75]  S. Peters,et al.  Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. , 2013, Lung cancer.

[76]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[77]  Susan S. Taylor,et al.  Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers , 2013, Cell.

[78]  Stacey Price,et al.  A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention , 2013, Cancer cell.

[79]  Jeanne Shen,et al.  Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[80]  Kaitlyn Le,et al.  Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib‐resistant melanoma cells , 2013, Pigment cell & melanoma research.

[81]  P. Bahadoran,et al.  Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[83]  A. Lazar,et al.  Clinical characteristics of melanoma patients with non-V600E/K BRAF mutations. , 2013 .

[84]  M. Therrien,et al.  Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization , 2013, Nature chemical biology.

[85]  D. Morrison,et al.  Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. , 2013, Molecular cell.

[86]  M. Dimon,et al.  Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo , 2013, Proceedings of the National Academy of Sciences.

[87]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[89]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[90]  Junfeng Xia,et al.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.

[91]  C. Pritchard,et al.  The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. , 2012, Genes & development.

[92]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[93]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[94]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[95]  A. von Deimling,et al.  Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.

[96]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[97]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[98]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[99]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[100]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[103]  K. Flaherty,et al.  BRAF, a target in melanoma , 2010, Cancer.

[104]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[105]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[106]  D. Heimbrook,et al.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.

[107]  J. Desai,et al.  PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. , 2010 .

[108]  Sabine Tejpar,et al.  Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery , 2010, The oncologist.

[109]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[110]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[111]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[112]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Jeffrey S. Morris,et al.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  D. Morrison,et al.  Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.

[115]  Marc Therrien,et al.  A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.

[116]  G. Clayman,et al.  Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. , 2009, Human Pathology.

[117]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[118]  D. Elder,et al.  CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations , 2009, Oncogene.

[119]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[121]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[122]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[123]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[124]  J. Frost,et al.  B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms* , 2005, Journal of Biological Chemistry.

[125]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[126]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[127]  T. Kawabe,et al.  Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor κB Pathway and Cellular Transformation , 2004, Cancer Research.

[128]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[129]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[130]  T. Kawabe,et al.  Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. , 2003, Cancer research.

[131]  K. Guan,et al.  Regulation of Raf through Phosphorylation and N Terminus-C Terminus Interaction* , 2003, Journal of Biological Chemistry.

[132]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[133]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[134]  J. Frost,et al.  Phosphorylation of Raf-1 by p21-activated Kinase 1 and Src Regulates Raf-1 Autoinhibition* , 2003, The Journal of Biological Chemistry.

[135]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[136]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[137]  R. Stephens,et al.  Autoregulation of the Raf-1 serine/threonine kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[138]  X. F. Zhang,et al.  Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues , 1994, Molecular and cellular biology.

[139]  David L. Brautigan,et al.  Raf-1 activates MAP kinase-kinase , 1992, Nature.

[140]  T. Bonner,et al.  The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. , 1987, Nucleic acids research.

[141]  F H Reynolds,et al.  Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[142]  Basket Study Yields Approval for Rare Cancer. , 2018, Cancer discovery.

[143]  P. Siegel,et al.  Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations , 2018 .

[144]  G. Linette,et al.  Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E , 2017, Melanoma research.

[145]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[146]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[147]  R. Kurzrock,et al.  BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. , 2015, Thyroid : official journal of the American Thyroid Association.

[148]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[149]  J. Wisell,et al.  Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma , 2013 .

[150]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[151]  A. Tefferi,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[152]  M. Gordon,et al.  RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models , 2010 .